Gosselies, Belgium (PRWEB) June 20, 2014
Euroscreen, a private drug development company, announced today that its ESN364 Phase I clinical candidate, will be presented at the ICE/ENDO Meeting on Sunday, June 22nd (Chicago, IL). Graeme Fraser, PhD, Director of Drug Discovery, will present the basis of its therapeutic application in the treatment of Women’s Health Disorders and disclose ESN364 development including First-In-Human preliminary data.
ESN364 is a proprietary, oral, small-molecule, discovered and optimized by Euroscreen. ESN364 is the first NK3 antagonist optimized for the purpose of the treatment of Women’s Health Disorders. "ESN364 represents a safe and powerful new approach for the treatment of diseases such as Endometriosis, Uterine Fibroids and PCOS (Poly Cystic Ovarian Syndrome). Its innovative mechanism of action provides a more refined modulation of the HPG axis and therefore the potential for a superior safety profile in comparison to the existing GnRH approaches" stated Dr. Jean Combalbert, CEO. “Our preliminary Phase I data exhibit the excellent safety of ESN364, and hormonal results obtained with Healthy Volunteers confirm our expectations in efficacy. Based on these favorable data, we should launch Phase II a clinical studies in early 2015. With ESN364, Euroscreen shows, once again, that it excels in discovering and developing innovative new drugs targeting the GPCR axis.”
Clinical Need and Market Opportunity
Endometriosis and Uterine Fibroids are serious public health concerns affecting approximately 10% of women around the world. GlobalData estimates that the combined global therapeutics market by 2018 for these two indications will be $2.8 billion. PCOS is another important disease with increasing incidence and a projected therapeutic market of $800 million by 2018. There are no broadly accepted therapies for this underserved market.
Euroscreen is a Belgium-based, private, Drug Discovery and Development company providing first-in-class small molecule drug candidates for therapeutic areas including hormonal disorders, inflammation and neurodegenerative diseases.
Euroscreen has a drug discovery track-record with multiple innovative and proprietary small-molecules targeting GPCRs.
Euroscreen has advanced its orally-available and highly specific lead program ESN364 into clinical development for the treatment of Women’s Health disorders. Euroscreen is also actively seeking partners for its preclinical development candidates, such as its ESN282 program for the treatment of inflammatory diseases such as Ulcerative Colitis.
Euroscreen is backed by leading investors, including Vesalius Biocapital, SRIW and Fortis Private Equity.
Further information about Euroscreen and its drug discovery and development programs can be found online at http://www.euroscreen.com or by contacting info(at)euroscreen(dot)com.